Core Insights - The Phase 3 EFZO-FIT™ study of efzofitimod demonstrated clinical benefits in patients with pulmonary sarcoidosis, particularly in improving fatigue and general health scores at week 48 compared to placebo [2][3][4] - Despite not meeting the primary endpoint of reducing mean daily oral corticosteroid dose, efzofitimod showed potential to improve multiple disease-related health outcomes, including cough, shortness of breath, and fatigue [3][4] Company Overview - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [2][9] - The company is investigating efzofitimod, a biologic immunomodulator, for treating interstitial lung disease (ILD), which includes pulmonary sarcoidosis and systemic sclerosis-related ILD [8][9] Study Findings - The study involved 268 patients and presented significant improvements in the Fatigue Assessment Scale Total Score (p=0.0226) and King's Sarcoidosis Questionnaire-General Health score (p=0.0197) for the 5.0 mg/kg efzofitimod treatment group [2][3][4] - Additional outcomes included a trend towards a greater proportion of patients achieving steroid-free status for at least six months and improvements in KSQ-Lung score [3][4] Treatment Context - Pulmonary sarcoidosis affects approximately 200,000 Americans, with current treatments primarily involving corticosteroids, which have limited efficacy and significant side effects [6][7] - Efzofitimod aims to provide a safer and more effective treatment option for patients with pulmonary sarcoidosis, potentially reducing reliance on chronic steroids [3][8]